Abstract
Objectives: This study aimed to [1] confirm that nonobese adolescents with polycystic ovary syndrome (PCOS) have higher anti-Mullerian hormone (AMH) than controls; [2] examine the relationship of AMH with PCOS features and hormonal profile; and [3] approximate an AMH value that discriminates between adolescents with PCOS and controls.
Design: Case-control study.
Setting: Subspecialty ambulatory clinic.
Patients: Thirty-one nonobese adolescent girls (age 13–21 years), 15 with PCOS diagnosed using the National Institutes of Health (NIH) criteria and 16 healthy control subjects. Subjects and controls were comparable for body mass index z-score, age and ethnicity.
Main outcome measure(s): AMH in PCOS subjects and control groups, correlation of AMH with hormonal parameters.
Results: AMH was higher in PCOS subjects (4.4±3.4 ng/mL) than in controls (2.4±1.3 ng/mL), when adjusted for menstrual age. In the entire group (PCOS and controls), AMH correlated with androgens, ovarian size and the presence of polycystic ovary (PCO) appearance. There was no difference in average ovarian size between PCOS (7.1±2.6 cm3) and controls (6.7±1.8 cm3). PCOS subjects were 1.49 times more likely to have AMH >3.4 ng/mL (confidence interval 0.98–2.26 ng/mL).
Conclusions: Our data suggest that AMH may be a useful adjunct in the diagnosis of PCOS in adolescents.
Acknowledgments
The authors thank Daniel Haisenleder, PhD, Associate Professor, Medicine, Endocrinology and Metabolism, School of Medicine, University of Virginia, for running the AMH assays.
References
1. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril 2012;97: 28–38.10.1016/j.fertnstert.2011.09.024Search in Google Scholar PubMed
2. Azziz R, Carmina E, Dewilly D, Diamanti-Kandarakis E, Excobar-Morreal HF, et al. The androgen excess and PCOS Society for polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88.10.1016/j.fertnstert.2008.06.035Search in Google Scholar PubMed
3. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston, MA: Blackwell Scientific Publications, 1992:377–84.Search in Google Scholar
4. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010;203:201.e1–5.10.1016/j.ajog.2010.03.008Search in Google Scholar PubMed
5. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165–74.10.2337/diab.38.9.1165Search in Google Scholar PubMed
6. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.10.1016/j.fertnstert.2003.10.004Search in Google Scholar PubMed
7. Brown M, Park AS, Shayya RF, Wolfson T, Su HI, et al. Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls. J Magn Reson Imaging 2013;38:689–93.10.1002/jmri.23992Search in Google Scholar PubMed PubMed Central
8. Park AS, Lawson MA, Chuan SS, Oberfield SE, Hoeger KM, et al. Serum anti-Mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab 2010;95:1786–92.10.1210/jc.2009-2106Search in Google Scholar PubMed PubMed Central
9. Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005;84:938–44.10.1016/j.fertnstert.2005.02.052Search in Google Scholar PubMed
10. Pigny P, Merlen E, Yann R, Cortet-Rudelli C, Decanter C, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–62.10.1210/jc.2003-030727Search in Google Scholar PubMed
11. Eilertsen TB, Vanky E, Carlsen SM. Anti-mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Human Reprod 2012;27:2494–502.10.1093/humrep/des213Search in Google Scholar PubMed
12. Pawelczak M, Kenigsberg L, Milla S, Liu Y, Shah B. Elevated serum anti-mullerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. J Pediatr Endocrinol Metab 2012;25:983–9.10.1515/jpem-2012-0013Search in Google Scholar PubMed PubMed Central
13. ACOG Committee Opinion. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol 2006;108:1323–8.10.1097/00006250-200611000-00059Search in Google Scholar PubMed
14. Armengaud J, Charkaluk M, Trivin C, Tardy V, Breat G, et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab 2009;94:2835–40.10.1210/jc.2009-0314Search in Google Scholar PubMed
15. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 2002:11 246:1–27.Search in Google Scholar
16. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7.10.1210/jcem-21-11-1440Search in Google Scholar PubMed
17. Rao CR. Linear statistical inference. New York: Wiley, 1973.Search in Google Scholar
18. Villarroel C, Merino PM, Lopez P, Eyzaguirre FC, Van Velzen A, et al. Polycystic morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 2011;26:2861–8.10.1093/humrep/der223Search in Google Scholar PubMed
19. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, et al. Antimullerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012;98:242–9.10.1016/j.fertnstert.2012.03.059Search in Google Scholar PubMed PubMed Central
20. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123–9.10.1093/humrep/der297Search in Google Scholar PubMed
21. Casadei L, Madrigale A, Puca F, Manicuti C, Emidi E, et al. The role of serum anti-Mullerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome. Gynecol Endocrinol 2013;29:545–50.10.3109/09513590.2013.777415Search in Google Scholar PubMed
22. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 2010;94:1118–21.10.1016/j.fertnstert.2009.11.002Search in Google Scholar PubMed
23. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332–40.10.1210/jc.2013-1393Search in Google Scholar PubMed
24. Hagen CP, Aksglaede L, Sorensen K, Main KM, Boas M, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010;95:5003–10.10.1210/jc.2010-0930Search in Google Scholar PubMed
25. Grynberg M, Pierre A, Rey R, Leclerc A, Arouche N, et al. Differential regulation of ovarian anti-Mullerian hormone (AMH) by estradiol through α- and β-estrogen receptors. J Clin Endocrinol Metab 2012;97:E1649–57.10.1210/jc.2011-3133Search in Google Scholar PubMed
©2014 by De Gruyter
